EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia

Sandra M Axiak-Bechtel iD, Stacey B Leach iD, Jessica R Newton-Northup, Rowan J Milner iD, Stacey A Fox-Alvarez, Lana I Fagman, Kaylee A Young, Deborah J Tate, Zachary M Wright, John D Chretin, Justin W Allen iD, Sean K Yoshimoto und 9 weitere

Journal of Veterinary Internal Medicine · 2023

DOI: 10.1111/jvim.16915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2023. Verfasst von Sandra M Axiak-Bechtel und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Neoplasms, Dog Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institute of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy beagle dogs. Hypothesis/Objectives The objectives of this study were to investigate the safety, peak plasma concentrations, and potential for efficacy of TCMCB07 in pet dogs with naturally occurring cachexia over a 4-week time period. Animals Fourteen dogs with cachexia of any underlying cause, except cancer of the oral cavity or gastrointestinal tract, were eligible for enrollment with informed client consent.

Methods

This study was a prospective, 1-armed open-label trial. Physical examination, complete blood count, chemistry panel, and owner-assessed quality of life surveys were checked at weeks 1, 2, and 4. Due to potential for bradycardia and hypotension, Holter monitoring and blood pressure evaluations were scheduled at pre-enrollment and week 4.

Results

Fourteen dogs completed the trial. Significant changes detected included increased mean body weight (18.6-19.5 kg, P < .02), increased body condition score (median Tufts 5-point thin dog scale score P < .004 and WSAVA muscle condition score P < .02) and increased mean blood urea nitrogen (21.79-30.43 mg dL−1, P < .004). On quality of life surveys, pet owners perceived their dog appeared to be panting less (P < .002) and that the general health improved (P < .03). Four dogs had a change in coat pigmentation. The peak plasma concentration of TCMCB07 in cachectic dogs was similar to that in healthy beagle dogs. Conclusions and Clinical Importance TCMCB07 was safe and has potential efficacy in pet dogs with cachexia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDog DiseasesHumansAnimalsDogsCachexiaProspective StudiesQuality of LifeMelanocortinsPeptides

Stichwörter der Autor:innen

anorexiacanineemaciationmetabolismtherapy

Substanzen

MelanocortinsPeptides

Autor:innen und Institutionen

  • Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, USA.
  • Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Missouri, USA.
  • TCI Peptide Therapeutics, Columbia, Missouri, USA.
  • VCA Animal Diagnostic Clinic, Dallas, Texas, USA.
  • VCA West Los Angeles, Los Angeles, California, USA.
  • VCA Family and Oahu Veterinary Specialty Center, Pearl City, Hawaii, USA.

ORCID-Profile: Sandra M Axiak-Bechtel, Stacey B Leach, Rowan J Milner, Justin W Allen, Michael Aherne

Förderung

  • NCI NIH HHS
  • National Institute of Health, National Cancer Institute

Zitieren

APA

Axiak-Bechtel, S. M., Leach, S. B., Newton-Northup, J. R., Milner, R. J., Fox-Alvarez, S. A., Fagman, L. I., Young, K. A., Tate, D. J., Wright, Z. M., Chretin, J. D., Allen, J. W., Yoshimoto, S. K., Selting, K. A., Flesner, B. K., White, C. R., Mills, T., Aherne, M., Bergman, P. J., Qi, L., …, & Callahan, M. F. (2023). Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.16915

Vancouver

Axiak-Bechtel SM, Leach SB, Newton-Northup JR, Milner RJ, Fox-Alvarez SA, Fagman LI, et al. Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia. Journal of Veterinary Internal Medicine. 2023. doi:10.1111/jvim.16915

BibTeX
@article{AxiakBechtel2023,
  author = {Axiak-Bechtel, Sandra M and Leach, Stacey B and Newton-Northup, Jessica R and Milner, Rowan J and Fox-Alvarez, Stacey A and Fagman, Lana I and Young, Kaylee A and Tate, Deborah J and Wright, Zachary M and Chretin, John D and Allen, Justin W and Yoshimoto, Sean K and Selting, Kimberly A and Flesner, Brian K and White, Carrie R and Mills, Tracy and Aherne, Michael and Bergman, Philip J and Qi, LeAnn and Gruber, Kenneth A and Callahan, Michael F},
  title = {Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2023},
  doi = {10.1111/jvim.16915}
}
Kostenlos starten →